Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Clozapine (LX 100129; HF1854, LX100129; Leponex; Fazaclo; CLOZARIL; Clozapin; Clozaril) is an atypical antipsychotic drug wand a 5-HT antagonist used in the treatment of schizophrenia. It binds to receptors for dopamine and serotonin. With its partial agonistic action at the 5-HT1A subunit of the serotonin receptor, clozapine may help alleviate symptoms of anxiety, depression, and negative cognitive symptoms linked to schizophrenia. There has also been evidence of clozapine's direct interaction with the GABAB receptor. Mice lacking the GABAB receptor show altered locomotor behavior and elevated extracellular dopamine levels similar to animal models of schizophrenia.
Targets |
5-HT2A Receptor ( Ki = 4 nM ); 5-HT6 Receptor; 5-HT7 Receptor; mAChR1 ( Ki = 9.5 nM ); mAChR4 ( Ki = 11 nM ); α2-adrenergic receptor ( Ki = 51 nM ); D2 Receptor ( Ki = 75 nM )
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C18H19CLN4
|
|
---|---|---|
Molecular Weight |
326.82
|
|
Exact Mass |
326.13
|
|
Elemental Analysis |
C, 66.15; H, 5.86; Cl, 10.85; N, 17.14
|
|
CAS # |
5786-21-0
|
|
Related CAS # |
Clozapine-d8; 1185053-50-2; Clozapine-d4; 204395-52-8; Clozapine N-oxide; 34233-69-7
|
|
Appearance |
Solid powder
|
|
SMILES |
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
|
|
InChi Key |
QZUDBNBUXVUHMW-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3
|
|
Chemical Name |
3-chloro-6-(4-methylpiperazin-1-yl)-11H-benzo[b][1,4]benzodiazepine
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.65 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.65 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 5%DMSO + Corn oil: 5.0mg/ml (15.30mM) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.0598 mL | 15.2989 mL | 30.5979 mL | |
5 mM | 0.6120 mL | 3.0598 mL | 6.1196 mL | |
10 mM | 0.3060 mL | 1.5299 mL | 3.0598 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02714894 | Active Recruiting |
Drug: Clozapine | Schizophrenia | Centre for Addiction and Mental Health |
April 2016 | N/A |
NCT04325386 | Active Recruiting |
Other: Education Sessions Other: No Education Session |
Schizophrenia Schizoaffective | University of Maryland, Baltimore | February 1, 2020 | Not Applicable |
NCT04074213 | Recruiting | Drug: Clozapine | Lymphoma Leukemia |
University Hospital, Caen | March 1, 2019 | N/A |
NCT05208190 | Recruiting | Drug: Clozapine Drug: treatment as usual |
Schizophrenia Schizoaffective Disorder |
New York State Psychiatric Institute |
March 17, 2022 | Phase 4 |
NCT05316883 | Recruiting | Drug: Clozapine | Schizophrenia Psychosis |
Mental Health Services in the Capital Region, Denmark |
February 28, 2021 | Phase 4 |